Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5275334 | 0.87 | CSNK1E (0.49) | CSNK1ECETP | |
| SCHEMBL14282188 | 0.81 | CTSK (0.42) | CETP | |
| SCHEMBL28010685 | 0.79 | POLB (0.43) | — | |
| SCHEMBL7097121 | 0.77 | TLR2 (0.42) | — | |
| SCHEMBL16898198 | 0.76 | TLL1 (0.41) | CETP | |
| SCHEMBL20587176 | 0.76 | TLL1 (0.41) | CETP | |
| SCHEMBL16898201 | 0.76 | TLL1 (0.41) | CETP | |
| SCHEMBL8910551 | 0.76 | PTGES (0.42) | CETP | |
| SCHEMBL7082482 | 0.74 | HTT (0.39) | — | |
| SCHEMBL16898430 | 0.74 | CTRC (0.39) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1287006-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2007-10-24 | — | — | EP | disclosed |
| US-7138547-B2 | Antitumoral compounds | PHARMA MAR, S.A. | 2006-11-21 | — | — | US | disclosed |
| US-20040048834-A1 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048834-A1 | Antitumoral compounds | HCCS, MSR1, SUCNR1 | CSNK1E 2673/4885CETP 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.